A Phase 1 Randomized Double-Blind Placebo-controlled Single and Multiple Ascending Dose Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis or Atopic Dermatitis
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs EDP-1815 (Primary)
- Indications Atopic dermatitis; Psoriasis
- Focus Adverse reactions; First in man
- Sponsors Evelo Biosciences
- 05 Nov 2019 According to an Evelo Biosciences Media Release, data will be presented at a future scientific conference or medical meeting.
- 05 Nov 2019 Interim results (N=18) presented in an Evelo Biosciences Media Release.
- 05 Nov 2019 According to an Evelo Biosciences media release, the company will host a conference call and webcast to review the new clinical data for EDP1815.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History